Shanghai Cell Therapy Group

The company was founded by Dr. Qian Qijun, who serves as chairman and general manager and is the largest single shareholder. Dr. Qian possesses approximately three decades of experience in the medical field, is a recipient of the National Outstanding Youth Science Foundation, and has served as the chief scientist for a national key R&D project in precision medicine. His extensive background in medical research, evidenced by numerous published SCI papers and patents in cell therapy, provides the scientific underpinning for the company's strategic direction.

The group's business is structured across four main segments: cell storage, oncology medicine, cell drugs, and cell enhancement products. Revenue is predominantly generated from its cell storage business, which holds the largest market share in China's immune cell storage market, accounting for nearly 79% of the company's total revenue in 2023. This service allows individuals to cryopreserve their immune cells for potential future therapeutic use. The company also provides oncology medical services through affiliated hospitals, offering cell therapy-based cancer treatments.

In its pursuit of therapeutic advancements, Shanghai Cell Therapy Group is developing a pipeline of cell-based drugs, with a strong focus on Chimeric Antigen Receptor T-cell (CAR-T) therapies for treating both hematological malignancies and solid tumors. The company has multiple drug candidates in clinical trials, including treatments for advanced malignant solid neoplasms. A key initiative is the "Baize Plan," which aims to provide affordable and effective cell treatments, cure cancer, and increase life expectancy. This plan includes overseas collaborations, such as a research project with the University of Southern California to improve the ex vivo expansion of hematopoietic stem cells.

Financially, the company has demonstrated consistent revenue growth, supported by multiple rounds of venture capital funding from investors including CCB International, Haier Capital, and Jiuzhou Venture Capital. Despite increasing revenues, the company has continued to post losses as it invests heavily in research and development and the commercialization of its therapies. In April 2024, Shanghai Cell Therapy Group submitted a prospectus to the Hong Kong Stock Exchange, signaling its intent to become a publicly-traded entity.